Business Context and Reporting Period
This Form 8-K was filed by Boundless Bio, Inc. (Nasdaq: BOLD) on August 19, 2024. The report details a corporate action taken by the compensation committee regarding the repricing of outstanding stock options for certain employees, including named executive officers.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to equity compensation adjustments:
- Repriced Exercise Price: Reduced to $3.56 per share (the closing stock price on August 19, 2024).
- Eligibility Threshold: Options with original exercise prices of $3.71 or greater were eligible for repricing.
Material Changes
The primary material change is the reduction of exercise prices for specific stock options to retain and motivate key contributors without issuing new equity or incurring significant cash compensation costs. The repricing is subject to a service condition known as the "Premium End Date."
- Premium End Date: The earliest of August 19, 2026, the date prior to a change in control, or the date of a Qualifying Termination.
- Reversion Clause: If an option is exercised or employment terminates (other than for a Qualifying Termination) before the Premium End Date, the original higher exercise price applies.
Guidance, Outlook, and Risks
The filing contains no forward-looking financial guidance, market outlook, or discussion of general business risks. The management commentary focuses solely on the strategic rationale for the option repricing: avoiding dilution from new grants and minimizing cash expenditures.
Unusual Items: The repricing affects the following named executive officers:
- Zachary D. Hornby (CEO): 1,147,242 options (original prices $4.10–$16.00).
- Klaus Wagner, M.D., Ph.D. (CMO): 316,893 options (original prices $4.10–$16.00).
- Chris Hassig, Ph.D. (CSO): 292,821 options (original prices $3.71–$16.00).
Investor Verification Checklist
- Verify the total number of options repriced across the entire employee base, as the filing only lists aggregates for named executive officers.
- Confirm the impact of the repricing on the company's share count and potential dilution if the Premium End Date conditions are met.
- Review the company's latest 10-Q or 10-K for current cash runway and liquidity status, as this 8-K does not disclose financial position.
- Monitor future filings for any changes in the "Premium End Date" or definitions of "Qualifying Termination."